Loading clinical trials...
Loading clinical trials...
Study to Show Non-inferiority of Tritanrix™-HepB/Hib-MenAC (+/- Hepatitis B Vaccine at Birth) Versus Tritanrix™-HepB/Hiberix™ Without Hepatitis B Vacc. at Birth for Antibody Response to All Vaccine Antigens Given in Healthy Infants
Conditions
Interventions
DTPw-HBV/Hib-MenAC conjugate vaccine
Locations
3
Philippines
GSK Investigational Site
Manila, Philippines
GSK Investigational Site
Quezon City, Philippines
GSK Investigational Site
Sampaloc, Manila, Philippines
Start Date
May 1, 2004
Primary Completion Date
March 1, 2005
Completion Date
March 1, 2005
Last Updated
September 16, 2016
NCT07203755
NCT07112144
NCT06947499
NCT06708286
NCT04429295
NCT05482282
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions